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SUMMARY
Introduction—The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase (AKT)/
mammalian target of rapamycin (mTOR) signaling pathway is frequently altered in head and neck
squamous cell cancer (HNSCC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K.
Preclinical models revealed synergy with docetaxel and a phase 1 trial demonstrated tolerability of
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this combination. This randomized phase 2 study evaluated PX-866 combined with docetaxel in
patients with advanced, refractory HNSCC.
Methods—Patients with locally advanced, recurrent or metastatic HNSCC who had received at
least one and no more than two prior systemic treatment regimens were randomized (1:1) to a
combination of docetaxel (75 mg/m2 IV every 21 days) with or without PX-866 (8 mg PO daily;
Arms A and B, respectively). The primary endpoint was progression free survival (PFS).
Secondary endpoints included objective response rate (RR), overall survival (OS), toxicity, and
correlation of biomarker analyses with efficacy outcomes.
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Results—85 patients were enrolled. There was a non-significant improvement in response rate in
the combination arm (14% vs. 5%; P = 0.13). Median PFS was 92 days in Arm A and 82 days in
Arm B (P = 0.42). There was no difference in OS between the two arms (263 vs. 195 days; P =
0.62). Grade 3 or higher adverse events were infrequent, but more common in the combination
arm with respect to diarrhea (17% vs. 2%), nausea (7% vs. 0%), and febrile neutropenia (21% vs.
5%); grade 3 or higher anemia was more frequent in arm B (7% vs. 27%). PIK3CA mutations or
PTEN loss were infrequently observed.
Conclusion—The addition of PX-866 to docetaxel did not improve PFS, RR, or OS in patients
with advanced, refractory HNSCC without molecular pre-selection.
Keywords
PIK3CA; PI3K; Docetaxel; Head and neck squamous cell cancer
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The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase (AKT)/mammalian target
of rapamycin (mTOR) signaling pathway is frequently altered in human cancers, leading to
cell proliferation, enhanced expression of survival genes and decreased expression of proapoptotic factors [1]. PI3K is an intracellular kinase comprised of the p110α, p110β, or
p110δ catalytic subunits, and a p85 regulatory subunit; mutations to p110α and p85 are
oncogenic [2,3]. Activating mutations to PIK3CA, the gene encoding the p110α catalytic
subunit of PI3K, are found in several tumor types, including glioblastoma (27%), breast
(18%), colorectal (16% of non-hypermutated tumors), cervical (33%), head and neck
squamous cell cancer (HNSCC; 6–8%), and non-small cell lung cancer (NSCLC; 2–6%)
[2,4–9]. Increased PIK3CA copy numbers are seen in prostate cancer (28%), squamous
histology NSCLC (33%), and HNSCC (45%) [10–12]. The phosphatase and tensin homolog
(PTEN) tumor suppressor gene, which inhibits PI3K signaling, may be lost via deletion
(25% of melanoma, breast, and prostate cancers), mutation, or epigenetic suppression [13–
16]. Lastly, upstream growth factor receptors that activate PI3K signaling, such as epidermal
growth factor receptor (EGFR) and insulin-like growth factor receptor, are often overexpressed in cancer [17,18].
PX-866 is a novel oral, pan-isoform inhibitor of PI3K [19]. In a phase 1 study, both PX-866
and docetaxel were given at their single agent maximal tolerated doses in patients with
advanced cancers [20]. The majority of adverse events (AE) were gastrointestinal and grade
≤2 similar to the single agent PX-866 trial [21]. Best response per Response Evaluation
Oral Oncol. Author manuscript; available in PMC 2016 May 05.
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Criteria in Solid Tumors (RECIST) 1.1 [22] was stable disease in over 50% of evaluable
patients at Week 6. Consistent with other studies investigating PI3K inhibitors, PIK3CA
mutations were associated with longer duration of stable disease, but this was not
statistically significant [21,23].
PX-866 had substantial antitumor efficacy in preclinical studies using a HNSCC patient
derived xenograft (PDX) model that occurred both in cases with and without a PIK3CA
activating genetic events [24]; in this same model an additive/synergistic effect was observed
in vivo with docetaxel (unpublished data). Docetaxel has been shown to be an active agent in
relapsed/metastatic (R/M) HNSCC in weekly and every 3 week regimens [25,26], is
considered an appropriate second/third line therapy by the National Comprehensive Cancer
Network (NCCN) guidelines, and has a toxicity profile that does not overlap with that of
PX-866.
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Therefore, we conducted an open-label, randomized, phase 2 trial comparing docetaxel
alone versus docetaxel plus PX-866 without the possibility of cross-over in patients with
R/M HNSCC in the second or third-line setting.

Patient and methods
Eligibility criteria
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Subjects had R/M HNSCC for which they had received 1–2 prior systemic therapies,
including up to one platinum-based chemotherapy regimen. Other key inclusion criteria
were age ≥18 years, measurable disease by RECIST 1.1 criteria [22], ECOG performance
status 0–1, life expectancy ≥3 months, and adequate hematologic, hepatic and renal function.
Treatment with any systemic anti-cancer or radiation therapy was not allowed within 4
weeks of study drug dosing. Patients with adequately treated and stable brain metastases
were eligible.
Salient exclusion criteria included known HIV infection; medical, social or psychological
factors affecting safety or compliance; grade ≥2 neuropathy; history of hypersensitivity to
docetaxel or other drugs formulated with polysorbate; pregnant/breastfeeding; prior
docetaxel for R/M HNSCC or within 6 months of enrollment in the curative setting; or any
prior treatment with a PI3K inhibitor. Each center’s institutional review board granted
approval and written informed consent was mandatory.
Treatment and efficacy assessments
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Patients were randomized to docetaxel 75 mg/m2 IV once every 21 days with or without
PX-866 8 mg by mouth daily in a 1:1 fashion without stratification factors. Colony
stimulating factors and anti-emetics were permitted in any cycle according to institutional
guidelines. All patients received dexamethasone 8 mg orally twice daily for 3 days starting
the day before docetaxel administration. Patients were evaluated for progression every 2
cycles. Patients continued therapy as long as they had stable disease or better per RECIST
1.1 criteria and lacked unacceptable toxicity or withdrawal of consent. Patients in the
combination arm were allowed to continue PX-866 alone after discontinuation of docetaxel.
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Safety assessments included vital signs, laboratory assessments and physical exams.
Adverse events (AEs) were assessed using the NCI Common Terminology Criteria for
Adverse Events (CTCAE) version 4.02. Up to two dose reductions were allowed for
docetaxel (60 and 45 mg/m2) and three dose reductions for PX-866 (6, 4 and 2 mg per day).
Subjects requiring additional dose reductions of PX-866 were removed from study. Study
drugs were discontinued if treatment needed to be delayed by more than two weeks.
Biomarker measurements
Optional archival tumor specimens were centrally evaluated for PIK3CA and KRAS
mutations, p16 and PTEN expression by immunohistochemistry (IHC) using a standard
clinical assay or as previously described [21,27].
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Statistics
The primary endpoint of this study was progression-free survival (PFS) and secondary
endpoints were objective response rate (ORR), incidence and severity of AEs, overall
survival (OS) and exploratory endpoints of biomarker correlations with efficacy. A docetaxel
alone control of median PFS of 3 months was assumed for the HNSCC study population.
With a 1-sided 0.20 false positive error rate, a projected 1-year enrollment period with an
additional 0.5 years of follow-up prior to analysis and a control over experimental hazard
ratio of 1.5, a total of 80 patients were required for the log-rank test with 0.80 power to
detect a statistically significant benefit in terms of lengthening PFS of the combination arm
of docetaxel plus PX-866 versus docetaxel alone.
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Results
Patient characteristics
Eighty-five patients were enrolled between November 2011 and June 2013. 42 and 43
patients were randomized to the PX-866 plus docetaxel (arm A) and docetaxel alone group
(arm B), respectively. Baseline characteristics were well balanced between the two arms.
The groups were similar with respect to numbers of prior systemic therapies and median
time since diagnosis Table 1.
Treatment delivered
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In arm A, 42 patients (100%) received at least one dose of PX-866 and/or docetaxel, while
41 patients (95%) in arm B received at least one dose of docetaxel. The median number of
docetaxel cycles administered was 3.5 (range, 1–13) and 4 (range, 1–12) in arms A and B,
respectively. The dose intensity of docetaxel was equivalent, with 70 mg/m2/cycle and 72
mg/m2/cycle in arms A and B, respectively. Thirty-four patients (81%) experienced a total of
97 dose interruptions or modifications of PX-866, with 61 (63%) of disruptions due to
adverse events. The most common reason for PX-866 dose disruptions was diarrhea, which
is consistent with the single agent toxicity of this agent. A total of 56 patients (29 in arm A
and 27 in arm B) were taken off study due to disease progression.
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Sixty-eight (80%) patients were evaluable for response as measured by RECIST 1.1 (35 in
Arm A, 33 in Arm B). There were no complete responses (CR) in either arm. There were 6
(14%) and 2 (5%) confirmed partial responses (PR) in arms A and B, respectively, a
difference that was not statistically significant (P = 0.13). There was one additional
unconfirmed PR in each arm. There were 9 (21%) and 8 (19%) patients receiving 7 or more
cycles in arms A and B, respectively (P = 0.79). There were no differences in the disease
control rates (CR + PR + stable disease [SD]) after 2 cycles that were 57% and 54% for
arms A and B, respectively (Table 2). Median PFS was 92 days (95% CI 46–119) for arm A
and 82 days (95% CI 47–96) for arm B (P = 0.42, Fig. 1). The PFS estimates at 3 months
were 50% (95% CI 33–65%) for arm A and 38% (95% CI 23–53%) for arm B, respectively.
The hazard ratio for PFS was 0.95 (95% CI 0.57–1.58). Median OS was 263 days in arm A
(95% CI 125–383) and 195 days in arm B (95% CI 121–NR; P = 0.62, Fig. 2).
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Human papillomavirus (HPV) and treatment efficacy
HPV testing was conducted centrally. Of the 49 patients with available tissue for analysis, 25
patients (51%) were HPV positive and 24 (49%) were HPV negative (Table 3). There were
15 HPV positive patients randomized to arm A, versus 10 that were allocated to arm B, an
imbalance that was not significant (P = 0.24). Out of the 17 patients that received therapy for
7 or more cycles, 7 (41%) were HPV positive, 4 (24%) were HPV negative, and 6 (35%) had
an unknown status. Out of the 8 patients that had a confirmed PR, 4 (50%) were HPV
positive, 1 (13%) was HPV negative, and 3 (37%) had an unknown status.
Genomics
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Of the 49 patients whose archival tumors were analyzed 4 (8%) had PIK3CA exon 9
mutations (3 G1633A, 1 A1634G; 3 in arm A and 1 in arm B; 3 HPV positive, 1 HPV
negative) while none had KRAS mutations. PTEN expression was reduced or absent in 3
patients (2 in arm A, 1 in arm B; 2 HPV positive, 1 HPV negative). PIK3CA mutation, and
PTEN IHC could not be correlated with PFS, ORR, or OS due to their rarity.
Safety and tolerability
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Eighty-three enrolled patients received at least one treatment on protocol and were
considered evaluable for safety (all 42 in arm A and 41 in arm B). In both arms most adverse
events were ≤2 (Table 4). There were more treatment related adverse events in arm A (all
grade, 281; grade 3–5, 85) compared to arm B (all grade, 186; grade 3–4, 43). Specifically in
arm A there was more diarrhea (64% vs. 22%), vomiting (57% vs. 15%), nausea (50% vs.
29%), electrolyte deficits (hypomagnesemia and hyponatremia both 19% in arm A and 7%
in arm B), rash (14% vs. 0%), and ALT/AST elevation (17% vs. 0%). There were similar
rates of infections (pneumonia and candidiasis at 17% and 12% in both groups, respectively)
between both arms. In terms of hematological toxicity, febrile neutropenia was more
common in arm A (21% vs.5%), but with more reported anemia in arm B (14% vs. 29%).
Six patients in arm A died during the study (1 related to toxicity; pneumonia) while 2
patients in arm B passed away during treatment. Three patients in arm A withdrew due to
AEs while 2 patients in arm B were taken off study due to toxicity.

Oral Oncol. Author manuscript; available in PMC 2016 May 05.

Jimeno et al.

Page 6

Author Manuscript

Discussion
This manuscript reports on a prospective, randomized study of docetaxel plus/minus a small
molecule inhibitor targeted against PI3K in relapsed or metastatic HNSCC patients.
Although the combination failed to improve outcomes compared to docetaxel alone, this is
one of the first prospective trials in the HPV era, and it showed a higher proportion of HPV
positive patients over HPV negative than expected, which has profound implications in trial
design. It also assessed a PI3K inhibitor targeting the protein product of PIK3CA, the gene
with the highest rate of activating mutations in HNSCC.
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The primary question of this trial was answered unequivocally; the addition of PX-866 to
docetaxel failed to improve PFS, ORR, or OS in patients with R/M HNSCC. The higher
observed response rate was not statistically significant (P = 0.13), though this may be a
reflection of a small sample size. However the PFS was only 10 days longer in the
combination arm, and OS estimates were non-significant. It is possible that the lack of
clinical benefit resulted from lack of molecular pre-selection in this study, as very few
tumors harbored genetic alterations (PIK3CA mutations, PTEN loss) thought to predict
sensitivity to PI3K inhibitors.
While it has been difficult to identify predictive biomarkers across all tumor types for this
class of drugs, preclinical and clinical data suggest that PI3K pathway activation may
correlate with sensitivity to PI3K inhibitors [24,28–30]. PX-866 has been efficacious in a
HNSCC PDX in cases with PIK3CA activating mutations or gene amplification, although
activity was also seen in cases without any such genetic events [24]. The data from the
PX-866 clinical experience as well for other PI3K inhibitors suggest that currently
identifiable pathway alterations are not always sufficient to predict efficacy [31].
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It is interesting to note that in this dataset of R/M HNSCC patients, 51% of those where
HPV status could be tested were positive. We did not identify significant differences in
treatment-related efficacy (either by response rate or by patients receiving more than 6
cycles, a surrogate for benefit) between HPV positive and HPV negative patients, but this
trial was not powered to address sub-group analyses.
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While the addition of PX-866 to docetaxel was reasonably well tolerated, toxicity appeared
to be more pronounced in the combination arm. This was particularly evident in the
incidence of GI toxicities (nausea, vomiting, and diarrhea), leading to electrolyte
imbalances. The data of this trial pertaining hematological toxicity is less consistent, since
there was more neutropenia but less anemia in the combination arm compared to docetaxel
alone; we do not have a readily available explanation for this dichotomy. Many of AEs are
consistent with other phase 1/2 studies evaluating PI3K inhibitors including our own phase 1
study [20], and the previously reported “twin” study in non-small cell lung cancer [32]. The
side effect profile was remarkably similar in our trial in HNSCC compared to the NSCLC
study, including the toxicity imbalances with the exception of neutropenia. To date, rash,
hyperglycemia, and transaminase elevations appear to be class effects of PI3K/AKT/mTOR
inhibition, although gastrointestinal side effects have been reported in studies as well [33].
However, in addition to PX-866 other PI3K inhibitors such as XL147 have reported a
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relative lack of glycemic toxicity [31]. Interestingly, despite more frequent adverse events in
the combination arm, the proportion of patients being taken off study due to toxicity was
similar between arms suggesting that the toxicity was manageable; similarly, the docetaxel
dose intensity was similar between arms, indicating that combination therapy did not lead to
less intense standard therapy administration.
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In summary, the addition of PX-866 to docetaxel did not improve clinical outcomes over
docetaxel alone in a molecularly unselected population of R/M HNSCC patients. Further
investigations with PI3K inhibitors in HNSCC should focus on appropriate biomarker or
histology selection to maximize the chances of clinical benefit. While PIK3CA activating
genetic events may predict sensitivity to this class of drugs, a solid link has been elusive,
challenging the hypothesis that PIK3CA mutations alone support oncogenesis and tumor
growth in contrast to other oncogenic mutations. Further exploration is needed to better
define molecularly those patients most likely to derive a benefit from such agents, since it is
likely that associated genetic events may help predict their utility.
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Fig. 1.

Kaplan–Meier curves for progression free survival (days).
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Fig. 2.

Kaplan–Meier curves for overall survival (days).

Author Manuscript
Oral Oncol. Author manuscript; available in PMC 2016 May 05.

Jimeno et al.

Page 12

Table 1

Author Manuscript

Patient characteristics.
PX-866 + docetaxel (n = 42)

Docetaxel (n = 43)

62 (36–81)

60 (40–82)

Female

4 (10%)

7 (16%)

Male

38 (90%)

36 (84%)

Caucasian

39 (93%)

37 (86%)

African American

3 (7%)

5 (12%)

Other

0 (0%)

1 (2%)

0

12 (29%)

8 (19%)

1

30 (71%)

35 (81%)

Stage at diagnosis I/II/III/IV (%)

2/5/14/79

5/9/16/70

Stage at baseline III/IV (%)

0 (0%)/42 (100%)

1 (2%)/42 (98%)

Prior anti-cancer therapy

42 (100%)

43 (100%)

Systemic therapy

27 (64%)

22 (51%)

Radiotherapy

10 (24%)

10 (23%)

Systemic/radiotherapy

35 (83%)

37 (86%)

Number of prior systemic therapies mean/range

1.7 (1–4)

1.7 (1–4)

Median time since diagnosis, months

18.0

20.2

Median age (range)

Sex

Ethnicity

ECOG
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Table 2

Author Manuscript

Response rate.a

a

PX-866 + Docetaxel (n = 42)

Docetaxel (n = 43)

Complete response

0

0

Partial response

6 (14%)

2 (5%)

Stable disease

18 (43%)

21 (49%)

Progressive disease

11 (26%)

10 (23%)

Not evaluable

7 (17%)

10 (23%)

Disease control rate (CR/PR/SD)

24 (57%)

23 (54%)

Response rate represent best overall response rate (investigator).
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Table 3

Author Manuscript

Treatment distribution by HPV status.

Author Manuscript

PX-866 + docetaxel (n = 42)

Docetaxel (n = 43)

HPV positive

15 (36%)

10 (23%)

PIK3CA mutation

3 (8%)

0 (0%)

7 or more cycles

6 (14%)

1 (2%)

Partial response

3 (7%)

1 (2%)

HPV negative

12 (28%)

12 (28%)

PIK3CA mutation

0 (0%)

1 (2%)

7 or more cycles

1 (2%)

3 (7%)

Partial response

1 (2%)

0 (0%)

Not available

15 (36%)

21 (49%)

PIK3CA mutation

0 (0%)

0 (0%)

7 or more cycles

2 (5%)

4 (9%)

Partial response

2 (5%)

1 (2%)
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Table 4

Author Manuscript

Adverse events occurring in 10% or more of one of the arms.
Adverse event

PX-866 + Docetaxel (n = 42)

Docetaxel alone (n = 41)

All grades

Grade ≥3

All grades

Grade ≥3

Anemia

6 (14%)

3 (7%)

12 (29%)

11 (27%)

Neutropenia

26 (62%)

26 (62%)

16 (39%)

15 (37%)

Thrombocytopenia

0 (0%)

0 (0%)

1 (2%)

0 (0%)

Febrile neutropenia

9 (21%)

9 (21%)

2 (5%)

2 (5%)

Abdominal pain

7 (17%)

2 (5%)

1 (2%)

0 (0%)

Diarrhea

27 (64%)

7 (17%)

9 (22%)

1 (2%)

Constipation

5 (12%)

0 (0%)

12 (29%)

0 (0%)

Nausea

21 (50%)

3 (7%)

12 (29%)

0 (0%)

Stomatitis

7 (17%)

0 (0%)

4 (10%)

2 (5%)

Vomiting

24 (57%)

2 (4%)

6 (15%)

0 (0%)

Fatigue

22 (52%)

3 (7%)

20 (49%)

4 (10%)

Peripheral edema

7 (17%)

0 (0%)

3 (7%)

0 (0%)

Candidiasis

5 (12%)

0 (0%)

5 (12%)

1 (2%)

Pneumonia

7 (17%)

5 (12%)

7 (17%)

4 (10%)

Weight loss

6 (14%)

0 (0%)

3 (7%)

1 (2%)

Dehydration

14 (33%)

0 (0%)

7 (17%)

0 (0%)

Hypokalemia

6 (14%)

3 (7%)

2 (5%)

0 (0%)

Hypomagnesemia

8 (19%)

0 (0%)

3 (7%)

1 (2%)

Hyponatremia

8 (19%)

6 (14%)

3 (7%)

3 (7%)

Transaminitis

7 (17%)

2 (5%)

0 (0%)

0 (0%)

Headache

6 (14%)

1 (2%)

3 (7%)

0 (0%)

Insomnia

9 (21%)

0 (0%)

2 (5%)

0 (0%)

Cough

9 (21%)

0 (0%)

7 (17%)

0 (0%)

Dyspnea

6 (14%)

1 (2%)

10 (24%)

4 (10%)

Oropharynx pain

2 (5%)

0 (0%)

5 (12%)

0 (0%)

Alopecia

6 (14%)

0 (0%)

4 (10%)

0 (0%)

Rash

6 (14%)

0 (0%)

1 (2%)

0 (0%)

Hypotension

5 (12%)

2 (5%)

6 (15%)

0 (0%)

Pyrexia

6 (14%)

0 (0%)

6 (15%)

0 (0%)

Hematological

Non-hematological
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